New immunotherapy combo aims to boost kidney cancer surgery success
NCT ID NCT07516366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot phase II trial tests whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery is safe and feasible for patients with high-risk clear cell kidney cancer that hasn't spread. Sixteen participants will receive the drugs and then undergo surgery to remove the tumor. The main goals are to see if most patients can complete treatment without major delays and to track side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- botensilimab and balstilimab (immunotherapy drugs)
- What this could lead to
- If successful, this could show that giving these immunotherapy drugs before surgery is safe and may help shrink kidney tumors, potentially improving outcomes for high-risk patients.
- What could go wrong
- This is a very small, early-phase trial with only 16 patients. It primarily tests safety and feasibility, not effectiveness. The drugs may cause side effects or not work as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer